Chédeville, Agathe L.Madureira, Patricia2021-03-042021-03-042021-02-01Cancers 13 (3): 542 (2021)2072-6694http://hdl.handle.net/10400.1/15166Glioblastoma (GB) (grade IV astrocytoma) is the most malignant type of primary brain tumor with a 16 months median survival time following diagnosis. Despite increasing attention regarding the development of targeted therapies for GB that resulted in around 450 clinical trials currently undergoing, radiotherapy still remains the most clinically effective treatment for these patients. Nevertheless, radiotherapy resistance (radioresistance) is commonly observed in GB patients leading to tumor recurrence and eventually patient death. It is therefore essential to unravel the molecular mechanisms underpinning GB cell radioresistance in order to develop novel strategies and combinational therapies focused on enhancing tumor cell sensitivity to radiotherapy. In this review, we present a comprehensive examination of the current literature regarding the role of hypoxia (O₂ partial pressure less than 10 mmHg), a main GB microenvironmental factor, in radioresistance with the ultimate goal of identifying potential molecular markers and therapeutic targets to overcome this issue in the future.engGlioblastoma (GB)HypoxiaRadiotherapyHypoxia Inducible Factor (HIF);RadioresistanceGlioma stem cells (GSC)journal article2021-02-0510.3390/cancers13030542